Myovant Sciences Ltd. – NYSE:MYOV
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Myovant Sciences Ltd. stock price monthly change
+0.26%
month
Myovant Sciences Ltd. stock price quarterly change
+0.71%
quarter
Myovant Sciences Ltd. stock price yearly change
+118.99%
year
Myovant Sciences Ltd. key metrics
Market Cap | 2.62B |
Enterprise value | 2.72B |
P/E | -14.05 |
EV/Sales | 7.19 |
EV/EBITDA | -19.43 |
Price/Sales | 6.89 |
Price/Book | -4.68 |
PEG ratio | -0.65 |
EPS | -2.21 |
Revenue | 230.97M |
EBITDA | -183.89M |
Income | -205.98M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -48.47% |
Oper. margin | -38.75% |
Gross margin | 73.03% |
EBIT margin | -38.75% |
EBITDA margin | -79.62% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMyovant Sciences Ltd. stock price history
Myovant Sciences Ltd. stock forecast
Myovant Sciences Ltd. financial statements
| Jun 2021 | 41.06M | -61.66M | -150.16% |
|---|---|---|---|
| Sep 2021 | 77.90M | -21.59M | -27.72% |
| Dec 2021 | 54.44M | -63.44M | -116.54% |
| Mar 2022 | 57.56M | -59.28M | -102.98% |
| 2022-10-26 | -0.45266 | -0.47 |
|---|
| Mar 2022 | 520011000 | 993.48M | 191.05% |
|---|---|---|---|
| Jun 2022 | 460130000 | 943.65M | 205.08% |
| Sep 2022 | 483974000 | 997.22M | 206.05% |
| Dec 2022 | 403521000 | 961.66M | 238.32% |
| Jun 2021 | -113.17M | -74.39M | 4.13M |
|---|---|---|---|
| Sep 2021 | 36.59M | -13.38M | 11M |
| Dec 2021 | -91.89M | 27.46M | 4.00M |
| Mar 2022 | -100.08M | 42.28M | 6.76M |
Myovant Sciences Ltd. alternative data
| Aug 2023 | 579 |
|---|---|
| Sep 2023 | 579 |
| Oct 2023 | 579 |
| Nov 2023 | 579 |
| Dec 2023 | 579 |
| Jan 2024 | 579 |
| Feb 2024 | 579 |
| Mar 2024 | 579 |
| Apr 2024 | 579 |
| May 2024 | 579 |
| Jun 2024 | 579 |
| Jul 2024 | 579 |
Myovant Sciences Ltd. other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2022 | 0 | 48635 |
| May 2022 | 0 | 1382 |
| Jul 2022 | 0 | 22866 |
| Aug 2022 | 0 | 31214 |
| Sep 2022 | 0 | 9243 |
| Oct 2022 | 0 | 22813 |
| Dec 2022 | 0 | 2241 |
| Jan 2023 | 0 | 17456 |
| Mar 2023 | 51599200 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | SUMITOMO CHEMICAL CO., LTD. 10 percent owner | Common Shares | 51,599,200 | $27 | $1,393,178,400 | ||
Sale | LANG MATTHEW officer: General .. | Common Shares | 1,272 | $26.89 | $34,204 | ||
Sale | ARJONA FERREIRA JUAN CAMILO officer: Chief Medical Officer | Common Shares | 1,109 | $26.89 | $29,821 | ||
Sale | MAREK DAVID C director, officer.. | Common Shares | 8,037 | $26.89 | $216,115 | ||
Sale | MAREK DAVID C director, officer.. | Common Shares | 8,037 | $26.89 | $216,115 | ||
Sale | MERENDINO LAUREN officer: Chief Commercial Officer | Common Shares | 2,008 | $26.89 | $53,995 | ||
Sale | LANG MATTHEW officer: General .. | Common Shares | 2,779 | $26.9 | $74,755 | ||
Sale | ARJONA FERREIRA JUAN CAMILO officer: Chief Medical Officer | Common Shares | 2,251 | $26.9 | $60,552 | ||
Sale | MEHRA UNEEK officer: Principal Financial Of.. | Common Shares | 2,241 | $26.75 | $59,947 | ||
Sale | MERENDINO LAUREN officer: Chief Commercial Officer | Common Shares | 1,703 | $25.2 | $42,916 |
| Quarter | Transcript |
|---|---|
| Q1 2022 27 Jul 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 10 May 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 26 Jan 2022 | Q3 2021 Earnings Call Transcript |
| Q2 2021 26 Oct 2021 | Q2 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. David C. Marek (1965) Chief Executive Officer & Director | $1,310,000 |
| Mr. Matthew Lang J.D. (1976) Gen. Counsel & Corporation Sec. | $1,030,000 |
Myovant Sciences: What The Sumitomo Offer Foretells
Myovant: Sumitomo Bid Is A Head Scratcher, Where Is The Value?
Myovant: Overvalued Despite Compelling Results From MYFEMBREE
Myovant Sciences: Regulatory Overhang Cleared
Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree
Myovant: Poised To Overcome Regulatory Issues
Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels
Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play
6 Top Biotech Ideas For 2022
-
When is Myovant Sciences Ltd.'s next earnings date?
Unfortunately, Myovant Sciences Ltd.'s (MYOV) next earnings date is currently unknown.
-
Does Myovant Sciences Ltd. pay dividends?
No, Myovant Sciences Ltd. does not pay dividends.
-
How much money does Myovant Sciences Ltd. make?
Myovant Sciences Ltd. has a market capitalization of 2.62B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 289.39% to 230.97M US dollars. Myovant Sciences Ltd. made a loss 205.98M US dollars in net income (profit) last year or -$0.47 on an earnings per share basis.
-
What is Myovant Sciences Ltd.'s stock symbol?
Myovant Sciences Ltd. is traded on the NYSE under the ticker symbol "MYOV".
-
What is Myovant Sciences Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Myovant Sciences Ltd.?
Shares of Myovant Sciences Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Myovant Sciences Ltd.'s key executives?
Myovant Sciences Ltd.'s management team includes the following people:
- Mr. David C. Marek Chief Executive Officer & Director(age: 60, pay: $1,310,000)
- Mr. Matthew Lang J.D. Gen. Counsel & Corporation Sec.(age: 49, pay: $1,030,000)
-
How many employees does Myovant Sciences Ltd. have?
As Jul 2024, Myovant Sciences Ltd. employs 579 workers.
-
When Myovant Sciences Ltd. went public?
Myovant Sciences Ltd. is publicly traded company for more then 8 years since IPO on 27 Oct 2016.
-
What is Myovant Sciences Ltd.'s official website?
The official website for Myovant Sciences Ltd. is myovant.com.
-
How can i contact Myovant Sciences Ltd.?
Myovant Sciences Ltd. can be reached via phone at +44 20 7400 3351.
Myovant Sciences Ltd. company profile:
Myovant Sciences Ltd.
myovant.comExchange:
NYSE
Full time employees:
579
Industry:
Biotechnology
Sector:
Healthcare
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
11-12 St. James’s Square
London, SW1Y 4LB
London, SW1Y 4LB
CIK: 0001679082
ISIN: BMG637AM1024
CUSIP: G637AM102
